Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients
Carman, J.S.; Bigelow, L.B.; Wyatt, R.J.
Journal of Clinical Psychiatry 42(3): 124-128
1981
ISSN/ISBN: 0160-6689 PMID: 6110654 Document Number: 182640
In a placebo-controlled double-blind crossover study lithium carbonate was added to the neuroleptic treatment of 11 chronic schizophrenic and 7 schizoaffective inpatients. Nurses' ratings of behavior indicated significant improvement in 8 patients in agitation or manic behavior, 5 patients in psychosis, and 5 patients in depression. A greater initial severity of symptoms, presence of affective symptoms and episodic course characterized the favorable response group. No neurotoxicity was encountered in this study.